Dror Ortho-Design Narrows Losses Amidst Cash Burn, Debt Surge

TL;DR

**DROR is burning cash and piling on debt to stay afloat, making it a highly speculative bet with no revenue in sight.**

AI Summary

Dror Ortho-Design, Inc. (DROR) reported a net loss of $653,528 for the three months ended September 30, 2025, a significant improvement from the $1,826,935 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $1,988,989, down from $4,642,188 in the prior year. The company's cash position decreased from $549,444 at December 31, 2024, to $240,362 at September 30, 2025. Total current liabilities surged to $2,420,477 as of September 30, 2025, from $906,738 at December 31, 2024, primarily due to the introduction of $801,658 in convertible promissory notes and a $478,285 derivative liability. Research and development expenses decreased to $151,456 for the three months ended September 30, 2025, from $451,030 in the prior year, reflecting reduced operational spending. The company continues to operate at a significant accumulated deficit of $21,495,645 as of September 30, 2025, and is dependent on external financing, having raised $1,100,000 from convertible debentures and warrants during the nine-month period and an additional $200,000 on November 12, 2025. DROR has not yet generated any revenues and remains in the research and development stage for its orthodontic alignment platform.

Why It Matters

For investors, DROR's continued lack of revenue and reliance on dilutive financing, such as the $1.1 million in convertible debentures, signals high risk and potential for further shareholder dilution. The substantial increase in current liabilities, including $801,658 in convertible promissory notes, indicates growing financial strain and a precarious liquidity position, which could impact the company's ability to fund its research and development. Employees face uncertainty given the company's going concern warning and dependence on future capital raises. Customers are not yet impacted as the company has not reached the sales stage, but its financial health will dictate future product availability. Competitively, DROR is far behind established players in the orthodontic market, needing significant capital and regulatory approvals to even begin competing.

Risk Assessment

Risk Level: high — The company explicitly states a 'going concern' warning due to recurring losses and an accumulated deficit of $21,495,645 as of September 30, 2025. Cash decreased by $309,082 during the nine months ended September 30, 2025, and total liabilities surged from $1,030,719 to $2,589,031, indicating significant financial instability and reliance on external capital.

Analyst Insight

Investors should avoid DROR given its 'going concern' warning, lack of revenue, and increasing debt burden. The company's reliance on dilutive financing and significant accumulated deficit make it a high-risk, speculative investment with no clear path to profitability.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$271,218

total Debt

$2,589,031

net Income

-$653,528

eps

-$0.00

gross Margin

N/A

cash Position

$240,362

revenue Growth

N/A

Key Numbers

• $21.5M — Accumulated Deficit (Increased from $19.5M at Dec 31, 2024, highlighting ongoing losses.)
• $1.99M — Net Loss (9 months) (Reduced from $4.64M in the prior year, showing some operational efficiency.)
• $240K — Cash Balance (Decreased from $549K at Dec 31, 2024, indicating significant cash burn.)
• $2.42M — Total Current Liabilities (Increased from $907K at Dec 31, 2024, primarily due to new debt instruments.)
• $1.1M — Proceeds from Convertible Notes (Raised during the nine months ended Sep 30, 2025, crucial for operations.)
• $801.7K — Convertible Promissory Notes (New liability as of Sep 30, 2025, contributing to increased debt.)
• $478.3K — Derivative Liability (New liability as of Sep 30, 2025, linked to financing activities.)
• $151.5K — R&D Expenses (3 months) (Decreased from $451K in Q3 2024, reflecting reduced investment in development.)
• 956,997,116 — Common Shares Outstanding (Consistent since Dec 31, 2024, but potential for future dilution from warrants and options.)
• $653.5K — Net Loss (3 months) (Significantly lower than $1.83M in Q3 2024, showing improved quarterly performance.)

Key Players & Entities

• Dror Ortho-Design, Inc. (company) — registrant
• SEC (regulator) — filing authority
• $21,495,645 (dollar_amount) — accumulated deficit as of September 30, 2025
• $1,988,989 (dollar_amount) — net loss for the nine months ended September 30, 2025
• $4,642,188 (dollar_amount) — net loss for the nine months ended September 30, 2024
• $240,362 (dollar_amount) — cash balance as of September 30, 2025
• $549,444 (dollar_amount) — cash balance as of December 31, 2024
• $1,100,000 (dollar_amount) — proceeds from convertible promissory notes during nine months ended September 30, 2025
• $801,658 (dollar_amount) — convertible promissory notes, net, as of September 30, 2025
• $478,285 (dollar_amount) — derivative liability as of September 30, 2025

FAQ

Risk Factors

• Significant Accumulated Deficit and Dependence on External Financing [high — financial]: The company has a substantial accumulated deficit of $21,495,645 as of September 30, 2025, indicating a history of significant losses. DROR relies heavily on external financing, having raised $1,100,000 from convertible debentures and warrants in the nine-month period and an additional $200,000 subsequently. This dependence creates a risk of not being able to secure future funding necessary for operations and development.
• Deteriorating Cash Position and Increasing Liabilities [high — financial]: The company's cash balance has decreased from $549,444 at December 31, 2024, to $240,362 at September 30, 2025. Concurrently, total current liabilities have surged from $906,738 to $2,420,477, driven by new convertible promissory notes ($801,658) and a derivative liability ($478,285). This combination of dwindling cash and rising short-term obligations poses a significant liquidity risk.
• Lack of Revenue and Early-Stage Development [high — operational]: DROR has not yet generated any revenue and remains in the research and development stage for its orthodontic alignment platform. This means the company has no proven market traction or revenue-generating capabilities, making its future success entirely dependent on the successful development and commercialization of its unproven technology.
• Potential Dilution from Convertible Instruments and Warrants [medium — financial]: The company has outstanding convertible promissory notes and warrants, which could lead to significant dilution of common stock upon conversion or exercise. The substantial number of common shares outstanding (956,997,116) already suggests a potentially diluted share structure, and future financing rounds involving these instruments could further reduce the value of existing shares.
• Uncertainty of Regulatory Approval for Medical Devices [medium — regulatory]: As an orthodontic alignment platform, DROR's products will likely require regulatory approval (e.g., FDA in the US) before they can be marketed. The process for obtaining such approvals can be lengthy, costly, and uncertain, posing a significant risk to the company's ability to bring its products to market.

Industry Context

The orthodontic market is competitive, with established players offering a range of solutions from traditional braces to clear aligners. Emerging technologies and direct-to-consumer models are also disrupting the space. Companies like DROR, focusing on innovative platforms, face challenges in gaining market share against incumbents and navigating the complexities of product development, regulatory approval, and patient/dentist adoption.

Regulatory Implications

As a developer of an orthodontic alignment platform, DROR's products will likely be subject to medical device regulations in its target markets. Obtaining necessary approvals (e.g., FDA in the US, CE marking in Europe) is a critical and potentially lengthy process that could impact time-to-market and overall viability. Failure to comply with evolving regulatory standards could lead to penalties or product recalls.

What Investors Should Do

1. Monitor future financing rounds closely for signs of dilution and assess the company's ability to secure sufficient capital to reach operational milestones.
2. Evaluate the progress of the orthodontic alignment platform's development and any indications of regulatory approval pathways or timelines.
3. Analyze the burn rate and cash runway, given the current low cash balance of $240,362 and significant operating expenses.
4. Assess the competitive landscape and DROR's unique selling proposition once product development progresses towards commercialization.
5. Consider the potential impact of convertible notes and warrants on future share price and ownership structure.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $653,528, improved from $1,826,935 in Q3 2024. Cash balance stood at $240,362, with current liabilities at $2,420,477.
• 2025-09-30: Nine months ended September 30, 2025 — Net loss was $1,988,989, down from $4,642,188 in the prior year. Raised $1,100,000 from convertible debentures and warrants.
• 2024-12-31: End of Fiscal Year 2024 — Cash balance was $549,444, and total current liabilities were $906,738.
• 2025-11-12: Additional Financing — Raised an additional $200,000, indicating ongoing need for capital beyond the reported period.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Highlights the company's long-term unprofitability and significant losses incurred to date, standing at $21,495,645 as of September 30, 2025.)

Convertible promissory notes

Debt instruments that can be converted into equity (stock) of the issuing company under certain conditions. (A new liability for DROR, totaling $801,658 as of September 30, 2025, contributing to increased debt and potential future equity dilution.)

Derivative liability

A financial instrument whose value is derived from an underlying asset, group of assets, or benchmark. It can create obligations for the company. (A new liability of $478,285 as of September 30, 2025, likely related to financing activities, adding to the company's financial obligations.)

Share-based compensation

Compensation provided to employees in the form of stock options, restricted stock, or other equity awards. (Significantly decreased from $1,854,726 for the nine months ended September 30, 2024, to $39,170 for the same period in 2025, indicating a reduction in equity-based incentives or a change in accounting treatment.)

Amortization of debt discount

The process of gradually expensing the difference between the face value of a debt instrument and its lower issue price over the life of the debt. (A new expense of $174,408 for the nine months ended September 30, 2025, related to the issuance of debt instruments at a discount.)

Year-Over-Year Comparison

Compared to the prior year, DROR has significantly reduced its net loss, with the nine-month loss down from $4.64 million to $1.99 million and the third quarter loss down from $1.83 million to $653,528. This improvement is largely due to a substantial decrease in R&D expenses, from $1.21 million to $715,128 for the nine months and from $451,030 to $151,456 for the quarter. However, the company's financial position has weakened, with cash decreasing from $549,444 to $240,362 and total current liabilities more than doubling from $906,738 to $2,420,477, primarily due to new debt instruments.

Key Financial Figures

• $0.0001 — he registrant's common stock, par value $0.0001 per share, as of November 18, 2025 was

Filing Documents

• ea0265282-10q_drorortho.htm (10-Q) — 501KB
• ea026528201ex4-1_dror.htm (EX-4.1) — 88KB
• ea026528201ex4-2_dror.htm (EX-4.2) — 109KB
• ea026528201ex10-1_dror.htm (EX-10.1) — 265KB
• ea026528201ex31-1_dror.htm (EX-31.1) — 10KB
• ea026528201ex31-2_dror.htm (EX-31.2) — 10KB
• ea026528201ex32-1_dror.htm (EX-32.1) — 4KB
• ea026528201ex32-2_dror.htm (EX-32.2) — 4KB
• 0001213900-25-112153.txt ( ) — 3773KB
• dror-20250930.xsd (EX-101.SCH) — 28KB
• dror-20250930_cal.xml (EX-101.CAL) — 21KB
• dror-20250930_def.xml (EX-101.DEF) — 150KB
• dror-20250930_lab.xml (EX-101.LAB) — 258KB
• dror-20250930_pre.xml (EX-101.PRE) — 159KB
• ea0265282-10q_drorortho_htm.xml (XML) — 276KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1 Item 1. Condensed Consolidated Financial Statements (Unaudited) 1 Notes to Unaudited Condensed Consolidated Financial 5 Item 2.

Management's Discussion and Analysis of Financial

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures about Market

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22

OTHER INFORMATION

PART II. OTHER INFORMATION 23 Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 27

Signatures

Signatures 28 i DROR ORTHO-DESIGN, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars, except share and per share amounts)

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements September 30, 2025 December 31, 2024 Unaudited Audited Assets Current Assets: Cash $ 240,362 $ 549,444 Receivables and prepaid expenses 10,419 89,139 Total Current Assets 250,781 638,583 Non-current Assets: Property and equipment at cost, net of accumulated depreciation 20,437 24,142 Total Assets 271,218 662,725 Liabilities And Stockholders' DEFICIT Current Liabilities: Accounts payable $ 447,250 $ 215,359 Accrued expenses and other payables 173,284 171,379 Convertible promissory notes, net 801,658 - Derivative liability 478,285 - Registration Rights Agreement liability 520,000 520,000 Total Current Liabilities 2,420,477 906,738 Non-current Liabilities: Accrued severance 168,554 123,981 Total Liabilities 2,589,031 1,030,719 Commitments and Contingencies (Note 6) Stockholders' Deficit Preferred A Stock, $ 0.0001 par value, 12,500,000 shares authorized; 5,847,937 shares outstanding at September 30, 2025 and December 31, 2024 585 585 Common stock, $ 0.0001 par value; 3,254,475,740 shares authorized; 956,997,116 shares issued and outstanding at September 30, 2025 and December 31, 2024 95,699 95,699 Additional paid-in capital 19,081,548 19,042,378 Accumulated deficit ( 21,495,645 ) ( 19,506,656 ) Total Stockholders' Deficit ( 2,317,813 ) ( 367,994 ) Total Liabilities and Stockholders' Deficit $ 271,218 $ 662,725 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 DROR ORTHO-DESIGN, INC. CONDENSED STATEMENTS OF OPERATIONS (U.S. dollars, except share and per share amounts) Three Months Ended Nine Months Ended September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024 Unaudited Unaudited Operating Expenses Research and development $ 151,456 $ 451,030 $ 715,128 $ 1,213,903 General and administrative expenses 318,424 307,593

View Full Filing

View this 10-Q filing on SEC EDGAR